Advicenne: TP ICAP Midcap slashes TP

(CercleFinance.com) - TP ICAP Midcap announced on Thursday that it had lowered its target price for Advicenne shares from E7.
3 to E4 per share, while renewing its buy recommendation on the stock.

In a note, the broker justifies its decision by integrating new assumptions around the pharmaceutical company, which specialises in the treatment of kidney disease.

To take into account the company's H1 performance, but above all the financial difficulties of its partner Primex, we are adopting a more cautious scenario, it explains.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.